Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

urrent collaboration. As a result, Anadys recognized $21.0 million of previously deferred revenue during the third quarter, representing the remaining unrecognized portion of the $20 million up-front payment and the $10 million IND milestone payment that were previously being recognized into revenue over the estimated development period of ANA975. Both amounts were received from Novartis in 2005. This completes the recognition of the deferred revenue under the Novartis collaboration. The Company reported revenues of $21.5 million for the third quarter of 2007, compared to $1.1 million for the third quarter of 2006.

Research and development expenses were $7.6 million for the third quarter of 2007 compared to $5.5 million for the third quarter of 2006. The $2.1 million increase was primarily due to an increase in external preclinical development costs for ANA773 and ANA598 and the effect of a one-time reimbursement of $1.1 million received during the three months ended September 30, 2006 for ANA975 costs previously incurred by Anadys. The increase was partially offset by a decrease in development costs associated with ANA975. As a result of our previously announced strategic restructuring, costs savings were achieved during the three months ended September 30, 2007 which were offset by severance related costs of $0.7 million.

General and administrative expenses were $2.4 million for the three months ended September 30, 2007 compared to $3.1 million for the three months ended September 30, 2006. The $0.7 million decrease is primarily due to a decrease in share-based compensation expense partially offset by separation related costs of $0.5 million related to our previously announced strategic restructuring and related reduction in force and the departure of our former President and Chief Executive Officer.

Operating expenses were $10.0 million for the quarter, compared to $8.6 million for the third quarter of 2006. Included as a component of Anadys' op
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2015)... , July 28, 2015 CSL Behring ... Administration has accepted for review the company,s Biologics License ... single-chain (rVIII-SingleChain) for the treatment of hemophilia A. In ... Hemophilia A is a ... VIII; nearly all affected patients are male. People with ...
(Date:7/28/2015)... , July 28, 2015  Faced with ... that are palliative rather than symptomatic, the global ... few existing therapies capable of curing or significantly ... are starting to look towards regenerative medicine as ... a new paradigm in human health with the ...
(Date:7/27/2015)... ... 27, 2015 , ... This is a professional and in-depth ... overview of the industry including definitions, classifications, applications and industry chain structure. The ... landscape analysis, and key regions development status. Development policies and plans are discussed ...
(Date:7/27/2015)... , July 27, 2015 Research presented at ... will expand on the studies that led to a ... diagnostic for this disease to receive approval from the ... to breaking Ebola,s grip on West Africa ... and enabling healthcare workers to isolate and treat these ...
Breaking Biology Technology:U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 2Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 3Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 4Stem Cell Therapy to Redefine Regenerative Medicine, says Frost & Sullivan 52015 Biophotonics Market Global Research 22015 Biophotonics Market Global Research 3Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 2Rapid Ebola Test Could Play Key Role in Efforts to End Lingering Outbreak 3
... combats an,alarming rise in chronic diseases, the Pharmaceutical ... new report on the next,generation of medicines in ... The report found that America,s pharmaceutical research ... - are,testing a record 633 new biotech medicines., ...
... and CHICAGO, Sept. 24 Omeros Corporation, a,Seattle-based ... million debt facility with BlueCrest Capital Finance. The ... by Omeros at closing and the,right, subject to ... $15,million. Other terms were not disclosed., "This ...
... specialty biopharmaceutical company,announces that at its Annual General Meeting today, all resolutions,contained in the notice of meeting ... ... Against Withheld** 1. To ... Emmens as a Director ...
Cached Biology Technology:New Report on 633 Biotechnology Medicines Under Development Released in Michigan 2New Report on 633 Biotechnology Medicines Under Development Released in Michigan 3Omeros and BlueCrest Announce $20 Million Debt Facility 2Results of the Annual General Meeting Held on September 24, 2008 2Results of the Annual General Meeting Held on September 24, 2008 3
(Date:6/30/2015)... HATFIELD, Pa. , June 30, 2015 ... joined the company as CEO to help further develop ... a wealth of partnering experience, having spent much of ... companies including Therakine, Amgen, Baxter Bioscience, and Johnson & ... a focus on Technology and Biotech Corporate Finance. He ...
(Date:6/26/2015)... Utah , June 26, 2015 ATL Technology, ... and devices with specialties in single use solutions, headquartered in ... of MedConx, Inc. (a California corporation ... and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing facility ...
(Date:6/25/2015)... SALT LAKE CITY , June 25, 2015 /PRNewswire/ ... the first steps toward a healthier, happier life. That,s ... app is designed to do. The cutting-edge, portable health ... and offers real-life solutions to help improve your lifestyle ... Sellers Association awards dinner and gala Wednesday night, USANA,s ...
Breaking Biology News(10 mins):Genisphere Appoints New CEO, Thomas Bliss 2Genisphere Appoints New CEO, Thomas Bliss 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2@USANAinc's Personalized Nutrition Program Wins Industry Innovation Award 2
... powerful class of antioxidants could one day be a potent ... antioxidants called synthetic triterpenoids blocked development of Parkinson,s in an ... days, said Dr. Bobby Thomas, neuroscientist at the Medical College ... of the study in the journal Antioxidants & Redox ...
... Award for Innovative Excellence, the Society,s highest award. ... Fulwyler, the inventor of the electrostatic cell sorter, and ... Dr. Terstappen received his Ph.D. in Applied Physics from ... pioneering cytometry research at Becton Dickinson. In 1994, ...
... July 23, 2012 Scientists at Joslin Diabetes ... (GLP-1), a gut hormone, protects against kidney disease, and ... findings, which are reported today online by Diabetes, may ... harness the actions of GLP-1 to prevent the harmful ...
Cached Biology News:Powerful class of antioxidants may be potent Parkinson's treatment 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 2The International Society for Advancement of Cytometry presented its 2012 awards at CYTO 2012 3Joslin researchers gain new understanding of diabetes and kidney disease 2Joslin researchers gain new understanding of diabetes and kidney disease 3
...
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
... primers are designed for sequencing inserts cloned ... T7, or T3 RNA polymerase promoters, or ... supplied at a concentration of 0.1 µg/µl ... in DNA sequencing reactions using SequiTherm™ EXCEL™ ...
BD BioCoat Matrigel Matrix 35 mm Culture Dishes Coating : BD MatrigelTM Basement Membrane Matrix ,Surface : ECM/attachment factors ,Surface area : 9.6 cm2 ,Dim nominal : 35 mm x 10 mm ,Vo...
Biology Products: